February 14th 2024
The drug development process, beginning with preclinical research up to when the product goes to market, requires time, risk, and high costs.
November 6th 2023
Pegloticase (Krystexxa; Amgen) is approved to treat chronic gout in adults who fail to normalize serum uric acid and whose signs and symptoms are inadequately controlled with xanthine oxidase inhibitors.
April 12th 2022
Series Part 3—Methods for early detection of risk and summary.
Series Part 2—The process of defining QTLs.
Series Part 1—Introduction and the relationship between QTL and KRI.